Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis

Author(s): Paolo Poggio*, Gianluca Folesani, Giuseppe M. Raffa, Paola Songia, Vincenzo Valenti, Veronika Myasoedova, Alessandro Parolari

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 8 , 2017

Become EABM
Become Reviewer
Call for Editor


Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification.

In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.

Keywords: Hypertension, aortic valve stenosis, antihypertensive drugs, ACEi/ARB, diuretics, alpa- beta-blockers, calcium channel blockers, vasodilators.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 12 April, 2017
Page: [1188 - 1194]
Pages: 7
DOI: 10.2174/1381612823666161123144534
Price: $65

Article Metrics

PDF: 50